English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduDr. Roy-Chaudhury will head up an organization—with nearly 21,000 health professionals representing 140 countries—dedicated to leading the fight against kidney diseases.
Tag: Kidney Transplantation
Researchers Test Imlifidase Enzyme Versus Plasma Exchange in Removing Donor-Specific Antibodies in Kidney Transplant Rejection Trial
For kidney transplant recipients experiencing antibody-mediated rejection, the current standard of care involves removing donor-specific antibodies (DSAs) through plasmapheresis (PLEX)—a procedure that removes antibodies from the plasma portion of the blood. Results from a recent clinical trial reveal that an investigational drug called imlifidase, which cleaves and inactivates the type of antibodies that include DSAs, is more effective than PLEX. The research will be presented at ASN Kidney Week 2024 October 23–27.
Preclinical Studies Test Novel Gene Therapy for Treating IgA Nephropathy
IgA nephropathy is an autoimmune kidney disease, and complement, a component of the innate immune system, plays a role in the condition’s pathogenesis. Investigators have developed and tested a novel gene therapy that enters kidney cells and enables them to block complement activation. The research will be presented at ASN Kidney Week 2024 October 23– 27.
Trial Assesses Antibody Therapy for Chronic Active Antibody-Mediated Kidney Transplant Rejection
Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients’ kidney function in a phase 2 trial. Investigators now have data from a phase 3 trial with clazakizumab. The findings from the Phase 3 IMAGINE trial, the largest placebo-controlled study in kidney transplant recipients with caAMR, will be presented at ASN Kidney Week 2024 October 23– 27.
High-Impact Clinical Trials Generate Promising Results for Improving Kidney Health: Part 2
The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23–27.
Do Certain Diabetes Drugs Increase the Risk of Acute Kidney Injury in Patients Taking Anti-Cancer Therapies?
Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear. Surprisingly, new research suggests that taking GLP-1RA is not associated with an increased risk of AKI in patients receiving anti-cancer therapies. The findings will be presented at ASN Kidney Week 2024 October 23– 27.
Global, National, and Regional Trends in the Burden of Chronic Kidney Disease among Women
A recent analysis reveals that the number of chronic kidney disease (CKD) cases in women around the globe nearly tripled in the past three decades. Also, type 2 diabetes and hypertension were the leading causes of CKD-related deaths in women. The research will be presented at ASN Kidney Week 2024 October 23– 27.
How the Novel Antibody Felzartamab Impacts IgA Nephropathy
IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase 2 trial revealed that felzartamab, an investigational anti-CD38 monoclonal antibody, helps to reduce proteinuria and maintain patients’ kidney function. Investigators evaluated the molecular mechanisms underlying felzartamab’s potential efficacy in IgAN. The findings will be presented at ASN Kidney Week 2024 October 23– 27.
Heart and Kidney Outcomes After Canagliflozin Treatment in Older Adults
Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on patients’ age. A recent analysis of clinical trial data reveals that the SGLT2 inhibitor canagliflozin benefited patients across all age categories. The findings will be presented at ASN Kidney Week 2024 October 23 – 27.
Researchers Integrate Multiple Protein Markers to Predict Health Outcomes in Individuals with Chronic Kidney Disease
Prior efforts to identify novel kidney biomarkers as risk factors for chronic kidney disease (CKD) progression have typically evaluated proteins individually, which limits their prognostic power. The National Institute of Diabetes and Digestive and Kidney Diseases’ (NIDDK’s) CKD Biomarkers Consortium of investigators recently developed and tested novel dimensions of kidney health by combining a set of 17 urine and plasma biomarkers that had been individually associated with CKD progression. The research will be presented at ASN Kidney Week 2024 October 23– 27.
The Clinical Significance of Microvascular Inflammation after Kidney Transplantation
Investigators recently uncovered key insights into newly defined rejection entities in kidney transplantation that may offer improved patient risk categorization post-transplant. The research will be presented at ASN Kidney Week 2024 October 23– 27.
Transplant doctor discusses how living kidney donors can help those in need of a transplant.
Eric Martinez, MD, at Baylor Scott & White Health, discusses how living kidney donors can help those in need of a transplant. What You Need to Know: Risk factors that could lead to kidney transplant include high blood pressure and…
BMI OrganBank, Atrium Health and LifeShare Carolinas Partner to Launch Nation’s First Organ Banking Technology
Atrium Health’s Division of Abdominal Transplant, Carolinas Medical Center (DAT Atrium), LifeShare Carolinas, one of nation’s leading Organ Procurement Organizations, and BMI OrganBank, a developer of organ perfusion systems based in Winston-Salem, North Carolina, announced today that their organizations have partnered to develop and launch the nation’s first Organ Banking technology, which will greatly expand the possibilities for organ preservation and reconditioning.
Study Shows Positive Outcomes for First Three U.S. Living HIV-To-HIV Kidney Transplant Donors
Based on findings from a study published today in the journal, The Lancet Regional Health – Americas, researchers at Johns Hopkins Medicine and three collaborating medical institutions suggest that people living with the human immunodeficiency virus (HIV) who donate a kidney to other people living with HIV (PLWH) have a low risk of developing end-stage kidney disease (ESKD) or other kidney problems in the years following the donation.
Waitlist Policies May Contribute to Racial Disparities in Access to Kidney Transplantation
• Racial disparities in access to kidney transplantation persist in the United States. New research indicates that registering Black patients on the kidney transplant waitlist at a slightly higher level of kidney function compared with white patients might lessen racial inequality in patients’ wait time prior to kidney failure onset, and ultimately improve racial equity in access to kidney transplantation.
Recent Efforts Haven’t Improved Access to Kidney Transplantation
• Despite wide recognition, policy reforms, and extensive research to address barriers in patients’ access to kidney transplantation, investigators found no improvement in rates of wait list placement and transplantation over 2 decades.
• Moreover, rates among vulnerable populations are especially low.
Study Examines Social Determinants of Disparities in Kidney Transplantation
• Race and social determinants of health were associated with the likelihood of undergoing kidney transplantation among US adults with kidney failure.
• Interventions that target social determinants of health may improve access to kidney transplantation.
Research News Tip Sheet: Story Ideas From Johns Hopkins Medicine
During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our “COVID-19 Tip Sheet: Story Ideas from Johns Hopkins” every other Tuesday.
Research News Tip Sheet: Story Ideas from Johns Hopkins Medicine
During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our “COVID-19 Tip Sheet: Story Ideas from Johns Hopkins” every Tuesday throughout the duration of the outbreak.
Inequities in Access to Kidney Transplantation Exist Even with Universal Healthcare
• In a study of patients with newly diagnosed kidney failure at 71 kidney centers in the UK, older age, additional illnesses, obesity, and lower socioeconomic status were associated with a lower likelihood of being put on transplant waiting list.
Study Examines Factors Affecting Racial Disparities Before Kidney Transplantation
• Among adults with kidney failure who were referred for transplantation, 60% of black and 66% of white patients were waitlisted within the first year. Differences in socioeconomic status and comorbidities between black and white patients could explain up to 58% of the disparity in listing.
• Fewer black patients on transplant wait lists received transplants compared with white patients, but differences in socioeconomic status and comorbidities did not explain this disparity.
Kidney Structural Features from Living Donors Predict Transplant Failure in Recipients
• Subtle structural features of donated kidneys—which were observed through biopsies taken at the time of donation—were associated with the longevity of organs after they were transplanted.